Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to enhance neurological symptoms of Ataxia-Telangiectasia (A-T); and GTX-101, a topical bio adhesive film-forming bupivacaine spray for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey. Show more

103 Carnegie Center, Princeton, NJ, 08540, United States

Biotechnology
Healthcare

Market Cap

37.92M

52 Wk Range

$1.79 - $5.18

Previous Close

$2.33

Open

$2.35

Volume

77,596

Day Range

$2.29 - $2.37

Enterprise Value

20.86M

Cash

16.98M

Avg Qtr Burn

-1.695M

Insider Ownership

25.73%

Institutional Own.

26.24%

Qtr Updated

03/31/26